Figure 1 | Scientific Reports

Figure 1

From: Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

Figure 1

IDFS for the whole cohort and each cohort group. Kaplan–Meier curves of IDFS in HER2-low group and HER2-zero group are shown. 5-year IDFS and the p values for the log-rank test between the HER2-low group vs. the HER2-zero group are reported in each figure panel. (A) IDFS in Whole Cohort. (B) IDFS in Cohort 1. (C) IDFS in Cohort 2. (D) IDFS in Cohort 3. IDFS invasive disease-free survival, HER2 human epidermal growth factor receptor 2. HER2-zero group: Patients with immunohistochemistry (IHC) 0 score. HER2-low group: Patients with IHC1+ or IHC2+/fluorescence in situ hybridization (FISH)—scores. Cohort 1: Patients with ≥ 4 positive axillary lymph nodes (ALNs), or 1–3 positive ALNs, and either histological grade (HG) 3 or tumor size ≥ 5 cm. Cohort 2: Patients with 1–3 positive ALNs, HG < 3, tumor size < 5 cm, and high Ki-67 index (≥ 20%). Cohort 3: Patients with 1–3 positive ALNs, HG < 3, tumor size < 5 cm, and low Ki-67 index (< 20%).

Back to article page